Cancer drug combo trial halted after only 9 patients
NCT ID NCT05036681
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, futibatinib and pembrolizumab, in people with a specific type of advanced endometrial cancer that had spread and was not responding to standard treatments. The goal was to see if the combination could shrink tumors and provide lasting control. However, the trial was stopped early after enrolling only 9 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tissue analysis may guide personalized cancer therapy
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a natural compound boost chemotherapy against endometrial cancer?
- Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?
- Can a new nucleotide analogue boost cancer treatment?